Crossmark

Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity

Crossref DOI link: https://doi.org/10.1038/s41590-025-02354-w

Published Online: 2026-01-02

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lim, Kok Haw Jonathan https://orcid.org/0000-0002-6544-9218
Schulz, Oliver

Lobon, Irene https://orcid.org/0000-0003-1170-9915
Castro-Dopico, Tomas https://orcid.org/0000-0002-6964-5478
Zapata, Luis

Giampazolias, Evangelos

Frederico, Bruno

Castellanos, Carlos A. https://orcid.org/0000-0003-3615-2009
Buck, Michael D. https://orcid.org/0000-0002-9611-1199
Stainier, William https://orcid.org/0009-0003-6182-4003
Chakravarty, Probir

Kelly, Gavin https://orcid.org/0000-0001-7219-560X
Rogers, Neil C. https://orcid.org/0000-0001-8977-7585
Cardoso, Ana

Lee, Sonia

Vash, Brian

Maiocco, Stephanie

Mehta, Raj

Strid, Jessica

Turajlić, Samra

Reis e Sousa, Caetano https://orcid.org/0000-0001-7392-2119
License Information

Text and Data Mining valid from 2026-01-01

Version of Record valid from 2026-01-02
More Information

Article History

Received: 20 August 2024

Accepted: 27 October 2025

First Online: 2 January 2026

Competing interests

: B.V. and S.M. are employees of Apple Tree Partners. R.M. is an employee of and owns stock options in Adendra Therapeutics, which partly funded this work. S.T. has received speaking fees from Roche, Astra Zeneca, Novartis and Ipsen. C.R.S. owns stock options and/or is a paid consultant for Adendra Therapeutics, Montis Biosciences and Bicycle Therapeutics. C.R.S. is a Visiting Professor at Imperial College London and King’s College London and holds an honorary professorship at University College London. The other authors declare no competing interests.

Document is current

Any future updates will be listed below